Maraviroc Disease Interactions
There are 3 disease interactions with maraviroc:
Maraviroc (applies to maraviroc) hepatotoxicity/liver impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Hepatotoxicity has been reported with the use of maraviroc. Severe rash or evidence of systemic allergic reaction (e.g., fever, eosinophilia, elevated immunoglobulin E [IgE]) prior to the development of hepatotoxicity may occur. Patients with signs/symptoms of hepatitis or allergic reaction after use of maraviroc should be evaluated immediately. Appropriate laboratory testing (including ALT, AST, and bilirubin) should be conducted before starting maraviroc and periodically during therapy as clinically indicated. Additional monitoring may be necessary when administering maraviroc to patients with preexisting liver dysfunction or who are coinfected with hepatitis B and/or C virus. The safety and efficacy of maraviroc has not been studied in patients with significant underlying liver disorders; caution is recommended.
Maraviroc (applies to maraviroc) renal impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
An increased risk of postural hypotension may occur in patients with severe renal dysfunction or in those with ESRD due to increased exposure to maraviroc in some patients. This drug should be used with caution in these patients only if they are not receiving a concomitant potent CYP450 3A inhibitor or inducer, but maraviroc should only be considered for patients with severe renal dysfunction or ESRD when no alternative treatment options are available. The dose should be reduced if any symptoms of postural hypotension occur. No studies have been performed in patients with severe renal dysfunction (CrCl less than 30 mL/min) or ESRD who are concomitantly taking potent CYP450 3A inhibitors or inducers, and maraviroc is contraindicated in these patients.
Maraviroc (applies to maraviroc) cardiovascular disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypotension
Cardiovascular events (including myocardial ischemia and/or infarction) were reported in 11 therapy-experienced patients (1.3%) receiving maraviroc during phase 3 trials; these patients generally had cardiac disease or cardiac risk factors before using maraviroc. Patients with cardiovascular comorbidities, history of/risk factors for postural hypotension, or receiving concurrent medication known to lower blood pressure, could be at increased risk of cardiovascular adverse events triggered by postural hypotension; additional monitoring may be necessary.
Maraviroc drug interactions
There are 311 drug interactions with maraviroc
Maraviroc alcohol/food interactions
There is 1 alcohol/food interaction with maraviroc
More about maraviroc
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 2 Reviews
- Drug class: chemokine receptor antagonist
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.